The Next Generation of Antivirals
Thylacine Bio is developing the Peptide Platform for Infectious Disease
our Approach
Treat illness, prevent infection, block transmission
Our therapeutics are designed to combat persistent endemic respiratory viruses of concern and help prepare for future outbreaks by treating disease, preventing infection, and blocking transmission.
Broad spectrum
inhibition
Pipeline candidates include commercial and biothreat therapeutics that protect against multiple pathogens within a family of viruses.
A resilient, scalable approach against emerging viruses.
Our platform can be rapidly tuned and applied to new and existing pathogens. We target conserved regions that are less susceptible to mutation, unlocking efficacy across variants. The resulting antivirals are potent, self-administered, and easily distributed.
meet the teamIn the News
